

SMITH & NEPHEW PLC
Form 6-K
November 19, 2009

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

Report of Foreign Private Issuer

**Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934**

November 19, 2009

Commission File Number 001-14978

SMITH & NEPHEW plc
(Registrant's name)

15 Adam Street
London, England WC2N 6LA
(Address of registrant's principal executive offices)

[Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.]

Form 20-F

Form 40-F

[Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).]

Yes

No

[Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).]

Yes

No

[Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing information to the

Edgar Filing: SMITH & NEPHEW PLC - Form 6-K

Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of 1934.]

Yes No X
--- ---

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2 (b) : 82- n/a.

Smith & Nephew Investor and Analyst Meeting

19 November 2009

Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, is holding an institutional investor and analyst meeting in Zurich, Switzerland starting today.

The purpose of the visit is to provide an opportunity to understand more fully the strategy and operations of Smith & Nephew's business units in Europe and the Emerging Markets, and to meet some members of our senior management team.

Presentations will be made between 12 noon and 2.30pm GMT (7am and 9.30am Eastern) on Thursday 19 November and between 7am and 11.30pm GMT (2am and 6.30am Eastern) on Friday 20 November 2009. The presentations at the event will be webcast live on Smith & Nephew's corporate website at www.smith-nephew.com. An archive of these presentations will be available on the website shortly after the end of the meeting.

No new material information will be disclosed, nor will there be any additional statement on current trading further to Smith & Nephew's Q3 Results statement on 6 November 2009.

Enquiries:

Investors/Analysts

Hannah Longbottom
Corporate Affairs Manager
Smith & Nephew plc

Tel: +44 (0) 20 7401 7646

Media

Jon Coles

+44 (0) 20 7404 5959

Brunswick – London

Cindy Leggett-Flynn

+1 (212) 333 3810

Brunswick – New York

About Us

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were \$3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Smith & Nephew Plc
(Registrant)

Date: November 19, 2009

By: /s/ Susan Henderson

Susan Henderson
Company Secretary